Overview

A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
This study is to assess the efficacy, safety, and tolerability of the investigational drug UCB0942in adult subjects with drug-resistant focal epilepsy across multiple centers in Europe.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Biopharma S.P.R.L.
Collaborator:
PRA Health Sciences